Search | Clinical Trials Finder

Conditions: Major Depressive Disorder
Interventions: AZD6765 iv, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Chino, California • Lond Beach, California • San Diego, California + 30 more

Conditions: Hypotension
Interventions: Attending real-time decision support, In-room real-time decision support, Attending feedback emails, In-room provider feedback emails, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Pager system, Central neuraxial anesthesia, Non-cardiac surgery, Propofol, Sevoflurane, Desflurane, Isoflurane, Ephedrine, Phenylephrine, Norepinephrine, Epinephrine, Dobutamine, Dopamine, Isoproterenol, Milrinone, Atropine, Glycopyrrolate, Vasopressin, Terlipressin, Sodium Chloride 0.9%, Ringer's lactate, Hydroxyethyl starch solutions, Fresh Frozen Plasma, Packed Red Blood Cells, Albumin solutions, Plasma-Lyte, Lidocaine, Bupivacaine, Levobupivacaine, Ropivacaine, Mepivacaine, Tetracaine, Prilocaine, Procaine, Chloroprocaine, Benzocaine, Articaine; Procedure · Device · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years to 100 Years
Enrollment: 22,435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Non-small Cell Lung Cancer
Interventions: Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo; Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 1,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 49
States / cities: Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more

Conditions: Hypertension
Interventions: Saline, QCZ484; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 64
States / cities: Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 59 more

Conditions: Pregnancy
Interventions: Normal Saline Infusion, Capped Epidural; Drug · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Post-operative Surgical Pain
Interventions: Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Thyroid Eye Disease, Graves' Orbitopathy
Interventions: Teprotumumab, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 9
States / cities: Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more

Conditions: Familial Hypoalphalipoproteinemia
Interventions: CER-001, Placebo; Drug
Lead sponsor: Cerenis Therapeutics, SA; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Arnold-Chiari Malformation, Posterior Fossa Tumors
Interventions: IV acetaminophen, normal saline; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cystic Fibrosis
Interventions: 7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS); Drug
Lead sponsor: CF Therapeutics Development Network Coordinating Center; Network
Eligibility: 4 Months to 59 Months
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 24 more

Conditions: Non-healing Wound
Interventions: CeFAZolin Injectable Solution; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Clostridium Difficile Infection (CDI)
Interventions: RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence); Drug
Lead sponsor: Rebiotix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 60
States / cities: Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more

Conditions: Advanced Cancer, Dehydration
Interventions: Saline; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Conroe, Texas • Houston, Texas

Conditions: Orbital Edema, Orbital Ecchymosis
Interventions: Tranexamic acid injection, Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML), normal saline - injection, normal saline - intravenous; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Tachycardia Atrial, Atrial Fibrillation, Atrial Flutter With Rapid Ventricular Response
Interventions: Magnesium Sulfate 2 G, Magnesium Sulfate 4 G, Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Uterine Cervical Dysplasia
Interventions: Amolimogene, Placebo; Drug · Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 13 Years to 25 Years · Female only
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 23 more

Conditions: Healthy
Interventions: Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more

Conditions: Analgesic Adverse Reaction
Interventions: Ketorolac Tromethamine, 0.9% Normal Saline; Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 2 Years to 18 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Albany, New York

Conditions: Knee Osteoarthritis
Interventions: NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF), 0.9% Sodium Chloride Injection, USP; Drug
Lead sponsor: Nova Vita Laboratory; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Pain, Postoperative, Ankle Fractures
Interventions: Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cleft Lip and Palate
Interventions: Ketorolac, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 6 Months and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Labor, Induced, Oxytocin
Interventions: Oxytocin; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Postoperative Pain
Interventions: Methadone, Saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Endocrine Tumors
Interventions: lanreotide (Autogel formulation), Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more

Search by objective public record fields.

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

Decision Support for Intraoperative Low Blood Pressure

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Efficacy of Labor Epidurals for Postpartum Tubal Ligation

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

Efficacy of Acetaminophen in Posterior Fossa Surgery

Infant Study of Inhaled Saline in Cystic Fibrosis

Antibiotic Tumescent For Chronic Wounds

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

Parenteral Hydration in Advanced Cancer Patients

The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery

Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy

NANOVAE to Treat Knee Osteoarthritis (KOA)

Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures

Ketorolac in Palatoplasty

Oxytocin Dosage to Decrease Induction Duration

Methadone Versus Placebo in Spine Fusion

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours